Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03041363Phase 1Completed

Treatment Development of Triheptanoin (G1D)

Role: lead

NCT02018315Phase 1Completed

Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)

Role: lead

NCT02018302Unknown

Post Study Continuation of C7 for G1D

Role: lead

NCT02021526Phase 1Withdrawn

Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)

Role: lead

All 4 trials loaded